Recently, our group has demonstrated that pretreatment with selective HDAC6 inhibitors such as nexturastat A and suprastat before treatment with anti-PD-1-blocking antibodies enhances the therapeutic efficacy of anti-PD-1 checkpoint blockade in melanoma and breast cancer mouse models by downregulating immunosuppressive molecules, decreasing protumoral M2 macrophages, and increasing T cell infiltration [98,120,121]. The gene discussed is PDCD1; the disease is melanoma.